4/26
07:07 am
vrtx
The Americas’ Fastest Growing Companies [FT.com - Mergermarket]
Low
Report
The Americas’ Fastest Growing Companies [FT.com - Mergermarket]
4/26
05:13 am
vrtx
The Americas’ Fastest Growing Companies [Financial Times (FT.com) (UK)]
Low
Report
The Americas’ Fastest Growing Companies [Financial Times (FT.com) (UK)]
4/26
05:06 am
vrtx
Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisis [Financial Times (FT.com) (UK)]
Low
Report
Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisis [Financial Times (FT.com) (UK)]
4/25
07:49 pm
vrtx
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know [Yahoo! Finance]
Low
Report
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know [Yahoo! Finance]
4/25
09:55 am
vrtx
2 Fantastic Growth Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
2 Fantastic Growth Stocks to Buy Right Now [Yahoo! Finance]
4/25
09:42 am
vrtx
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies [Seeking Alpha]
Low
Report
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies [Seeking Alpha]
4/23
10:06 am
vrtx
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies [Yahoo! Finance]
Low
Report
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies [Yahoo! Finance]
4/23
09:17 am
vrtx
Vertex in-licenses cell therapy technology for diabetes candidates [Seeking Alpha]
Low
Report
Vertex in-licenses cell therapy technology for diabetes candidates [Seeking Alpha]
4/23
07:37 am
vrtx
Global Vaccine Contract Manufacturing Market Trends Analysis Report 2024-2030: Capacity Expansion by Contract Manufacturers, & Vaccination Innovation and Robust Vaccine Pipeline Bolsters Growth [Yahoo! Finance]
Low
Report
Global Vaccine Contract Manufacturing Market Trends Analysis Report 2024-2030: Capacity Expansion by Contract Manufacturers, & Vaccination Innovation and Robust Vaccine Pipeline Bolsters Growth [Yahoo! Finance]
4/23
06:26 am
vrtx
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis [Seeking Alpha]
Low
Report
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis [Seeking Alpha]
4/23
05:54 am
vrtx
U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline and Growing Prevalence of Target Diseases Fueling Growth and Developments [Yahoo! Finance]
Low
Report
U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline and Growing Prevalence of Target Diseases Fueling Growth and Developments [Yahoo! Finance]
4/23
03:45 am
vrtx
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Low
Report
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
4/23
12:55 am
vrtx
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES [Yahoo! Finance]
Low
Report
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES [Yahoo! Finance]
4/23
12:45 am
vrtx
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Low
Report
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
4/23
12:45 am
vrtx
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Low
Report
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
4/23
12:45 am
vrtx
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Low
Report
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
4/22
07:27 am
vrtx
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today [Yahoo! Finance]
Low
Report
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today [Yahoo! Finance]
4/20
09:51 am
vrtx
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever [Yahoo! Finance]
Low
Report
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever [Yahoo! Finance]
4/20
02:02 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
4/19
07:06 pm
vrtx
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know [Yahoo! Finance]
Low
Report
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know [Yahoo! Finance]
4/19
02:09 pm
vrtx
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug [Yahoo! Finance]
Low
Report
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug [Yahoo! Finance]
4/18
09:11 am
vrtx
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain [Yahoo! Finance]
Low
Report
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain [Yahoo! Finance]
4/18
08:04 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at UBS Group AG from $498.00 to $466.00. They now have a "buy" rating on the stock.
Medium
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at UBS Group AG from $498.00 to $466.00. They now have a "buy" rating on the stock.
4/18
08:04 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Guggenheim from $445.00 to $450.00. They now have a "buy" rating on the stock.
Medium
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Guggenheim from $445.00 to $450.00. They now have a "buy" rating on the stock.
4/18
08:00 am
vrtx
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Low
Report
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain